Subscribe to GlobalData Explorer to access actionable intelligence spanning 22 industries, 200+ economies and 700k+ companies on a single platform

Number of ongoing Clinical Trials (for drugs) involving Oligodendroglioma by Phase

  • There are currently 66 ongoing clinical trials involving Oligodendroglioma

  • Of the 66 trials,23 trials are in Phase II

  • Furthermore, 21 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Oligodendroglioma by Phase

Published: October 2021
Source: GlobalData

The global pharmaceutical industry is steadily developing new drugs for Oligodendroglioma, an Oncology condition. The largest number of ongoing clinical trials for Oligodendroglioma is conducted in the North America region. Asia-Pacific and Europe are among some of the other prominent regions engaged in Oligodendroglioma-related drug trials. 

St. Jude Children’s Research Hospital Inc: The leading ongoing Oligodendroglioma related clinical trial sponsor 

St. Jude Children’s Research Hospital Inc is the top sponsor for Oligodendroglioma-related ongoing clinical trials. 

Memorial Sloan Kettering Cancer Center, Novartis AG, University of California San Francisco and Beijing Sanbo Brain Hospital are among other notable clinical trial sponsors involved in Oligodendroglioma. A clinical trial sponsor can be a Company, Government, Individual, or Institution. 

Marketed Drugs involving Oligodendroglioma  

Carmustine (Bicnu, Becenun, Carmubris, Carmustine Avet), Procarbazine (Matulane / Natulan) and Vincristine sulfate (Oncovin) are among the key marketed drugs involving Oligodendroglioma. 

Carmustine (Bicnu, Becenun, Carmubris, Carmustine Avet) acts as an alkylating agent. It functions via DNA Synthesis Inhibitor mechanism of action. Carmustine is formulated as lyophilized powder for solution and solution for intravenous route of administration. Carmustine was first approved in 1975 and is marketed globally in the US, UK, Australia, Canada, Germany, and France by several prominent pharma giants including Avet Pharmaceuticals Inc. 

Procarbazine (Matulane / Natulan) is a benzamide derivative acts as anti-neoplastic agent. It functions via DNA Synthesis Inhibitor mechanism of action. Procarbazine is formulated as hard gealtin capsules for oral route of administration. Procarbazine was first approved in 1965 and is marketed globally in the US, France, Germany, Russia and Japan by several prominent pharma giants including Leadiant Biosciences Inc. 



Explore, track and compare industries, economies and companies in a single platform through GlobalData Explorer.​

Single License $700 per month (billed Annually)
Multiple Licenses Connect with a GlobalData representative to discover our offers for multiple licenses​
  • 700K+Companies
  • 22Industries
  • 15K+Reports
  • 200+Countries & Regions
Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward